首页> 外文期刊>Nature reviews. Endocrinology >Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus
【24h】

Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus

机译:药物治疗:抗高血糖药在2型糖尿病患者中的心血管安全性

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Two large trials published in the New England Journal of Medicine demonstrate that the dipeptidyl peptidase 4 (DPP4) inhibitors alogliptin and saxagliptin are safe in patients with type 2 diabetes mellitus (T2DM). Concerns have been raised over the past few years regarding the cardiovascular safety of new therapies for T2DM, particularly sulphonylureas and rosiglitazone. As a result, the FDA and regulatory agencies in other countries now require that the cardiovascular safety of all new diabetes drugs be assessed.
机译:在《新英格兰医学杂志》上发表的两项大型试验表明,二肽基肽酶4(DPP4)抑制剂阿格列汀和沙格列汀在2型糖尿病(T2DM)患者中是安全的。在过去的几年中,人们对新的T2DM疗法,尤其是磺酰脲类药物和罗格列酮的心血管安全性提出了担忧。结果,其他国家的FDA和监管机构现在要求评估所有新的糖尿病药物的心血管安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号